Pre-clinical studies have successfully demonstrated that ALK can be targeted using CAR T-cell immunotherapy, although cell surface levels may be too low in some neuroblastomas for productive engagement by some CAR-targeting moieties [24]. This evidence concerns the gene ALK and neuroblastoma.